CD19 and leukemia: Interestingly, in vitro data and in vivo mouse models have shown that, unlike conventional anti-CD19 CAR-T cells, ZA-stimulated anti-CD19 Vγ9Vδ2 CAR-T cells from healthy donors can target both CD19+ and CD19- allogeneic leukemia cells via the non-specific MHC-independent cytotoxic activity elicited by pAgs stimulation (137).